The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
The study was a multi-center, single-arm, prospective, non-interventional observational study in postmenopausal women with osteoporosis who had been treated with Prolia® for osteoporosis in routine clinical practice.
Study Type
OBSERVATIONAL
Enrollment
935
Percentage of Participants With Persistence With Prolia® at 12 Ponths
A participant was considered persistent with Prolia® at 12 months if they received at least 2 Prolia® injections no more than 6 months plus 8 weeks (239 days) apart.
Time frame: 12 months
Percentage of Participants With Persistence With Prolia® at 24 Months
A participant was considered persistent with Prolia® at 24 months if they received at least 4 Prolia® injections and the length of time between any 2 consecutive Prolia® injections does not exceed 6 months plus 8 weeks (239 days).
Time frame: 24 months
Time to Non-persistence
For non-persistent participants, time to non-persistence was calculated as the time between the date of the first injection and the date of last injection received during the period where the participant was still classified as persistent plus 6 months (183 days).
Time frame: 24 months
Number of Prolia® Injections Received
The number of injections that a participant received over 24 months (including the baseline injection) regardless of when the injection was received.
Time frame: 24 months
Percentage of Participants Satisfying Medication-taking Behavior at 12 Months
Percentage of participants satisfying medication-taking behavior defined as, following the first Prolia® injection, the participant received a second Prolia® injection and the length of time between the first and the second Prolia® injection did not exceed 6 months with a grace period of ± 4 weeks.
Time frame: 12 months
Percentage of Participants Satisfying Medication-taking Behavior at 24 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Birmingham, Alabama, United States
Research Site
Chandler, Arizona, United States
Research Site
Peoria, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Hemet, California, United States
Research Site
Laguna Hills, California, United States
Research Site
Los Angeles, California, United States
Research Site
Murrieta, California, United States
Research Site
Oxnard, California, United States
Research Site
Santa Maria, California, United States
...and 79 more locations
Percentage of participants satisfying medication-taking behavior defined as the participant received all 4 Prolia® injections and the length of time between any 2 consecutive Prolia® injections did not exceed 6 months with a grace period of ± 4 weeks.
Time frame: 24 months